Upcoming events

Apr 2017

2017-04-01 00:00:00.000000
7-9 Apr 2017
PCR Tokyo Valves 2017

Tokyo

Japan

May 2017

2017-05-01 00:00:00.000000
16-19 May 2017
EuroPCR 2017

Paris

France

Supported by

Stents and scaffolds

Here you will find all the latest content on stents and scaffolds published on this website. Results are listed in chronological order.

Since 1986, when the first cardiovascular stent was implanted, the development of drug-eluting stents (DES) and the recent introduction of bioresorbable scaffolds have revolutionised interventional cardiology. Keep up-to-date with the latest research; evolving tools, devices and techniques; the role of adjunctive pharmacotherapy; advances in imaging techniques as well as the use of invasive imaging and functional assessment. Find out more…

Filtered By
Stents and scaffolds

456 results

Highlights from ACC 2017

How important was interventional cardiology at this year’s American College of Cardiology Scientific sessions? Join D. Capodanno as he reviews the breaking sessions and others to reveal what aspects of our specialty were touched on during this recent international meeting and why. From structural and coronary to imaging, as well as important developments in pharmacology see which issues had the greatest impact: Was it iFR or FFR?  TAVI? New agents? Cost effectiveness?  Get your “take-home” message here…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC 17).

What to expect in interventional cardiology in 2017

PCR Chair William Wijns gives us his take on 2017: expanded indications for TAVI, new BRS data, trials on device based therapies in arterial hypertension, launch of Stent Save a Life, slow implementation of interventional treatment of acute ischemic stroke, celebrating 40 years of balloon angioplasty and EuroPCR 2017. An exciting year lies ahead!

Lessons from the ABSORB everolimus-eluting bioresorbable vascular scaffold programme

P. Serruys offers an overview and evaluation of the past, ongoing and upcoming clinical trials regarding the Absorb everolimus-eluting bioresorbable vascular scaffold (BRS). Were the concerns generated by earlier trials justified? What impact has this had on the current ABSORB III trial, and has this trial provided us with the results we expected after 1 or 2 years from this device? What will new iterations of this device have to offer? Understand the essential BVS message from a recognised expert …

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).

ABSORB III Trial: Two-year outcomes

Absorb everolimus-eluting bioresorbable vascular scaffold (BRS) vs. XIENCE stent? We join S. Ellis, the study’s lead author, as we examine our evolving understanding of BRS in this non-inferiority trial. What were the principal endpoints and results? What was the cause of an observed “increase in risk”? Did this impact the study results? What lessons have we learned? Vessel size? Technique? Join us as we examine a device which is still challenging, but increasingly understood…

This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).

How we arrived here: understanding the BVS bioresorbable coronary scaffold today

01 Mar 2017

The special article by Patrick W. Serruys and Yoshinobu Onuma on the impact of implantation techniques for the BVS bioresorbable coronary scaffold deserves a word of introduction.

ABSORB III at 2 years: more events, more difference

19 Mar 2017

ABSORB III presented at ACC consolidate the understanding that bioresorbable scaffolds carry a higher risk of target lesion failure compared with their metallic counterpart

LIVE case: a mid LAD PCI with BRS

From AsiaPCR/SingLIVE 2017

Consult this LIVE case a mid LAD PCI with BRS, with LIVE demonstration from National Heart Insititute, Malaysia.

A 49-year-old with an atypical chest pain:
•    Single vessel disease
•    Overlapped BRS
•    OCT assessment

Rosli Mohd Ali

Operator

Mohd Ali Rosli

Operator

Shaiful Azmi Bin Yahaya

LIVE case: RCA long lesion BRS OCT

From EuroPCR 2015

Consult this LIVE case on PCI of a long lesion of the RCA with 2 BVS showing optimal deployment by using “overlapping technique” and guided by OCT.

A 66-year-old female with multivessel disease:

  • LAD was previously treated with BVS.
Prof. Christian Hamm

Operator

Christian Hamm
Holger Nef

Operator

Holger Nef

At the crossroads of BRS development: food for thought

31 Jan 2017

 
It is clear that we have reached a crossroads with the new technology which we call the "fully bioresorbable scaffold". Today, the community is somewhat insecure about the future of this new technology which is currently still in its early iterations.

Wrap up interview: Cre8™ - How innovative technology enhances PCI clinical outcome

Is there a real difference in DES today, especially when it comes to answering the unmet needs involved in the treatment of the diabetic patient? Can an innovative polymer-free DES with a unique AmphilimusTM formulation provide a higher level of safety and efficacy? Join R. Mohd Ali, Kuala Lumpur, Malaysia along with J. Tan, Singapore and P. Stella, The Netherlands as they discuss the latest data and positive results of the polymer-free DES Cre8TM – an emerging tool in the armamentarium of the interventional cardiologist.